Patent foramen ovale

Area of Science:

• Cardiology
• Neurology
• Vascular Medicine

Background:

• Patent foramen ovale (PFO) is a common heart defect causing an interatrial shunt.
• PFO can lead to paradoxical embolism, resulting in stroke, myocardial infarction, or ischemia.
• PFO is a recognized risk factor for stroke and may be linked to migraine with aura.

Purpose of the Study:

• To evaluate the efficacy of percutaneous PFO closure in preventing recurrent ischemic stroke.
• To identify specific patient subgroups who benefit from PFO closure.
• To compare PFO closure plus antiplatelet therapy versus antiplatelet therapy alone.

Main Methods:

• Analysis of new evidence on PFO closure in stroke survivors.
• Focus on a highly selected population: patients ≤60 years with cryptogenic stroke, large right-to-left shunt, atrial septal aneurysm, and no atrial fibrillation.
• Comparison of outcomes between percutaneous PFO closure plus antiplatelet therapy and antiplatelet therapy alone.

Main Results:

• Percutaneous PFO closure, when added to antiplatelet therapy, reduces the risk of recurrent ischemic stroke in a carefully selected group of younger stroke survivors.
• This benefit is observed in patients with specific criteria including cryptogenic stroke syndrome, large shunts, and atrial septal aneurysm.
• Current evidence does not support PFO closure for migraine treatment.

Conclusions:

• PFO closure is a beneficial adjunctive therapy for specific young stroke survivors to prevent recurrent ischemic events.
• Patient selection is critical for successful PFO closure outcomes.
• PFO closure is not indicated for migraine management based on current data.